Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Effects of GLP-1 RAs on Human Lactation Outcomes

University of Colorado, Denver · NCT07720414

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Any age listed · Women only
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
18
US sites recruiting
1
Study start
July 2026
Record last updated
July 22, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

There is increasing interest in using GLP-1 Receptor Agonist (GLP-1 RA) medications after pregnancy. This study is designed to determine if these medications affect breastmilk production or the nutritional makeup of breastmilk.

The main questions the study will address are:

  • Does GLP-1 RA-induced weight loss increase or decrease breastmilk production?
  • Does GLP-1 RA-induced weight loss affect the nutritional composition of milk, including milk fat content?

Researchers will assess milk production rates before and after mothers begin taking injected GLP-1 RA medications to decrease their body weight. Weight loss will be confirmed with 7-day body weight averages.

Participants will

  • Weigh themselves and report measurements daily.
  • Participate in 2-3 morning study visits over approx. 2.5-4.5 months (approx. 3-3.5hrs each).

During each visit, participants will:

  • Use a study provided breastpump to express milk 3 times hourly for measurement of hourly milk production.
  • Provide 1-3 oz of milk for further study.
  • Answer questions about breastfeeding patterns.

Being studied: Injected GLP-1 Receptor Agonists and Dual Agonists

Conditions: Lactation; Weight Loss

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Breastfeeding mothers of single or multiple infants.
  • Milk removal at least 4x daily
  • Eligible for a GLP-1 RA administered subcutaneously (oral GLP-1 RAs contain absorption enhancers, which may drive accumulation in milk)
  • Access to a breastpump, if needed for maintaining breastfeeding behaviors.
  • Willingness to provide 1-3 oz of breastmilk per study visit.
  • Willingness to track and report body weight daily.
  • Willingness to maintain breastfeeding behaviors for the duration of the study.

Exclusion Criteria

  • Currently taking GLP-1 RA medication or other weight loss medication
  • Induced lactation, due to unknowns regarding the durability of the mammary gland's milk production after exogenous stimulation.

Recruiting US locations

  • University of Colorado Anschutz School of Medicine

    Aurora, CO 80045

Study contacts (from the official record)

  • Jayne F Martin Carli, PhD · 303-724-3981 · jayne.martincarli@cuanschutz.edu
  • Jacinda M Nicklas, MD, MPH · 303-724-9028 · jacinda.nicklas@cuanschutz.edu
All weight loss studies in Colorado →
Effects of GLP-1 RAs on Human Lactation Outcomes (NCT07720414) | Bored Studies